
Stem Cell Therapy Holds Promise for Kidney Disease
By Denise Mann HealthDay Reporter | HealthDay Thu, Aug 4, 2011
THURSDAY, Aug. 4 (HealthDay News) -- Researchers may be
one step closer to harnessing the power of stem cells to help treat,
and potentially cure, kidney disease.
Two new studies, both
published in a recent issue of the Journal of the American Society
of Nephrology, demonstrate that kidney cells can be reprogrammed to
morph into other types of kidney cells needed to repair damage.
In one report, scientists out of Monash University in Australia
extracted kidney cells and reprogrammed them so they could behave
like other kidney cells. In a second related study, researchers from
the Chinese Academy of Sciences in Guangzhou, China, collected
kidney cells from urine and were also able to reprogram them.
The next step is to see if the cell lines -- called induced
pluripotent stem cells (iPSC) -- can be expanded, and then injected
back into people with kidney disease to develop functional tissue
and/or organs. While this may be years off and there are many steps
left to take, the technology has the potential to cure certain
hereditary forms of kidney disease and acute kidney injury, and
could eliminate the need for dialysis and/or kidney transplants in
some patients with end-stage kidney disease.
Dr. Ivonne
Schulman, an assistant professor of clinical medicine and
nephrologist at the University of Miami's Interdisciplinary Stem
Cell Institute in Florida, said that this is the first time that
researchers have shown that kidney cells could be reprogrammed and
made to behave like embryonic stem cells, meaning they have the
potential to differentiate into other types of kidney cells.
"Two papers back-to-back show that two different kidney cell types
are able to be reprogrammed," she said. "This is very significant."
The ultimate goal would be to inject these cells back into
patients and try to regenerate kidney tissue, Schulman explained.
"It could theoretically help all types of kidney disease," she said.
"It just depends on the ability of these cells to differentiate back
into the cell types needed for that disease."
In one of the
studies, researchers were able to collect the kidney cells from
urine, which means that they could be collected at anytime,
eliminating the need for cell banks. "This makes it very simple,"
Schulman added.
Dr. Jeffrey I. Silberzweig, co-medical
director of the Rogosin Institute Manhattan Dialysis Center in New
York City, said that the benefits could be exponential. "The idea
that you can have the ability to do stem cell transplants during the
early stage of kidney disease and regenerate the damaged part of the
kidney would be a tremendous benefit for patients and the country as
a whole," he said.
The current treatment for end-stage kidney
disease includes dialysis and/or kidney transplantation. Dialysis,
which outsources kidney function, is uncomfortable, time-consuming
and costly, he noted. Plus, "the supply of kidneys available for
transplantation is way behind the number of people who need them,"
Silberzweig said. Intervening earlier with stem cell therapy could
prevent things from ever getting that far.
"If it reaches a
point where this technology becomes practical, patients would fall
over each other getting in line to do it," Silberzweig said.
"This is a critical and important first step," said Dr. Samuel
Saltzberg, a transplant nephrologist at Rush University Medical
Center in Chicago. "We have quite a way to go to get to a point
where we can impact kidney disease -- especially in diseases when
the whole organ needs to be repaired."
In an editorial
accompanying the new studies, Dr. Ian Rogers of Mount Sinai Hospital
in Toronto wrote that kidney disease may just be the tip of the
iceberg. "The advantage of these cells for the diagnosis and
treatment of kidney disease is great -- but the ease of collection
and the high frequency of reprogramming also means there may be
benefits to urine cells for iPSC production beyond kidney disease."
|